The Respiratory Syncytial Virus (RSV) season typically runs from November 1 through March 31. There has been an increase in RSV in children across Pennsylvania and around the country. CDC surveillance has shown an increase in RSV detections and RSV-associated emergency department visits and hospitalizations in multiple U.S. regions, with some regions nearing seasonal peak levels. Clinicians and public health professionals should be aware of increases in respiratory viruses, including RSV. RSV usually causes mild, cold-like symptoms:

Most RSV symptoms will resolve on its own in 1-2 weeks with supportive care.

For some children, RSV symptoms can be more severe and can also cause lower respiratory infections like bronchiolitis and pneumonia. One to two percent of children younger than 6 months of age with RSV infection may need to be hospitalized. Severe disease most commonly occurs in very young infants. Additionally, children with any of the following underlying conditions are considered at high risk:

• Premature infants
• Very young infants, especially those 6 months and younger
• Children younger than 2 years old with chronic lung disease or congenital heart disease
• Children with suppressed immune systems
• Children who have neuromuscular disorders, including those who have difficulty swallowing or clearing mucus secretion
  

Based on interim guidance published by the American Academy of Pediatrics (AAP) on August 26, 2022, Health Partners Plans (HPP) will consider the use of Synagis (palivizumab) in patients who would be candidates per current eligibility requirements before the typical start of the RSV season. Synagis is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV in infants and children at high risk.

If you have questions, please contact our Provider Services Helpline at 1-888-991-9023, Monday – Friday, 9 a.m. – 5:30 p.m. Thank you for your support in providing the highest quality of care to our members.